Monday, February 24, 2014

Sporadic Fatal Insomnia in an Adolescent

Case Report

 

Sporadic Fatal Insomnia in an Adolescent

 

Jennifer L. Blase, MPHa, Laura Cracco, PhDb, Lawrence B. Schonberger, MDa, Ryan A. Maddox, PhDa, Yvonne Cohen, BSb, Ignazio Cali, MSb, and Ermias D. Belay, MDa + Author Affiliations

 

aDivision of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and bNational Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, Ohio Abstract The occurrence of sporadic prion disease among adolescents is extremely rare. A prion disease was confirmed in an adolescent with disease onset at 13 years of age. Genetic, neuropathologic, and biochemical analyses of the patient’s autopsy brain tissue were consistent with sporadic fatal insomnia, a type of sporadic prion disease. There was no evidence of an environmental source of infection, and this patient represents the youngest documented case of sporadic prion disease. Although rare, a prion disease diagnosis should not be discounted in adolescents exhibiting neurologic signs. Brain tissue testing is necessary for disease confirmation and is particularly beneficial in cases with an unusual clinical presentation.

 


 
UPDATE ;


 Monday, February 24, 2014

Sporadic Fatal Insomnia in an Adolescent

http://sporadicffi.blogspot.com/2014/02/sporadic-fatal-insomnia-in-adolescent.html



a response to this case from the Doctors that treated ;


Comment on Sporadic Fatal Insomnia in an Adolescent
  a.. Michael Tennison, Professor of Neurology and Pediatrics
  b.. Heather Baudet M.D. Ph.D., Joseph Muenzer M.D. Ph.D.
UNC Chapel Hill
We read with interest the report by Blas? et al. as we were the physicians who actually cared for the child. We learned that this manuscript was in press upon contacting the National Prion Disease Pathology Surveillance Center (NPDPSC) to include them in our own manuscript. We were disappointed and surprised that the CDC "case

More...
We read with interest the report by Blas? et al. as we were the physicians who actually cared for the child. We learned that this manuscript was in press upon contacting the National Prion Disease Pathology Surveillance Center (NPDPSC) to include them in our own manuscript. We were disappointed and surprised that the CDC "case investigation" did not include speaking with the physicians who treated the patient. It is difficult to extract nuances of a case from a medical record without firsthand knowledge of the patient. The restrictions of space allow us to correct only some of the errors in the manuscript. The presenting symptom was diplopia, which in retrospect is characteristic of sporadic fatal insomnia (sFI). Subsequently, the most prominent symptoms were non-specific incoordination and cognitive changes with very prominent pseudobulbar affect and anxiety. There was a stepwise deterioration after two head injuries followed by strabismus surgery. A major abrupt decline then occurred with a H1N1 illness. Hyperkinetic is imprecise and ballismus is an incorrect characterization of the movements which were appendicular and gait cerebellar ataxia. The authors inaccurately state that no evaluation of insomnia or dysautonomia was performed. In fact, the family reported that the patient had difficulty sleeping only toward the end of his life despite direct questioning at each visit and declined a sleep study when offered. The child did develop incontinence as an autonomic issue but had no cardiovascular or vasomotor changes. We believe no reasonable clinician would stop pursuing alternative diagnoses based solely on polysomnogram or PET results. Head injury was never "diagnostically deceptive" to the neurology team. Could head injury, like surgery and severe influenza, be a trigger for a step-wise deterioration in sFI? A mitochondrial disorder was initially considered as the patient had a de novo POLG1 gene variant (p.V742M), but an outside mitochondrial expert agreed with the pursuit of alternate explanations, including prion-related disorders. The authors fail to note that two of the treating physicians independently raised the possibility of a prion disease. Therefore, the statement that a prion diagnosis was not pursued is false. In March of 2011 after further deterioration, the NPDPSC declined free-of-charge PRNP sequencing stating that the clinical picture was inconsistent with prion disease. We then pursued in-house analysis of the PRNP gene, specifically looking for the permissive methionine at codon 129 as well as the D178N mutation known to cause fatal familial insomnia. Brain biopsy would have potentially been diagnostic and was considered. We felt that the likelihood of a treatable diagnosis being discovered on brain biopsy was small and elected to defer to autopsy. Without aggressive pursuit of a prion diagnosis, amongst others, and counseling about the need for autopsy, a diagnosis would have never been reached. Rather than procuring our notes via the state health department and using our observations and assessments without citation, we believe including the treating physicians who actually saw the patient in the investigation and manuscript would have avoided inaccuracies and inferior science.

Conflict of Interest:
None declared



Published April 28, 2014

http://pediatrics.aappublications.org/content/133/3/e766.abstract/reply#pediatrics_el_59985


Seems (to me at least), Belay et al are always trying to sway the verdict (or diagnosis), again.

for one thing, the statement;


‘’There was no evidence of an environmental source of infection,’’


HOW hard did they look (cjd questionnaire, and questions pertaining to this questionnaire, if there was one at all), and how far back in this adolescents case history did they go back?


I think this statement says it all ;


‘’In March of 2011 after further deterioration, the NPDPSC declined free-of-charge PRNP sequencing stating that the clinical picture was inconsistent with prion disease.’’


nuff said. ...it’s what they do$$$


i am reminded of a few things deep throat told me 15 years or so ago, and it holds true today ;


*** The most frightening thing I have read all day is the report of Gambetti's finding of a new strain of sporadic cjd in young people.........

Dear God, what in the name of all that is holy is that!!! If the US has different strains of scrapie..... why???? than the UK... then would the same mechanisms that make different strains of scrapie here make different strains of BSE... if the patterns are different in sheep and mice for scrapie..... could not the BSE be different in the cattle, in the mink, in the humans....... I really think the slides or tissues and everything from these young people with the new strain of sporadic cjd should be put up to be analyzed by many, many experts in cjd........ bse..... scrapie

Scrape the damn slide and put it into mice..... wait..... chop up the mouse brain and and spinal cord........ put into some more mice..... dammit amplify the thing and start the damned research..... This is NOT rocket science... we need to use what we know and get off our butts and move.... the whining about how long everything takes..... well it takes a whole lot longer if you whine for a year and then start the research!!!

Not sure where I read this but it was a recent press release or something like that: I thought I would fall out of my chair when I read about how there was no worry about infectivity from a histopath slide or tissues because they are preserved in formic acid, or formalin or formaldehyde..... for God's sake........ Ask any pathologist in the UK what the brain tissues in the formalin looks like after a year....... it is a big fat sponge... the agent continues to eat the brain ...... you can't make slides anymore because the agent has never stopped........ and the old slides that are stained with Hemolysin and Eosin...... they get holier and holier and degenerate and continue... what you looked at 6 months ago is not there........ Gambetti better be photographing every damned thing he is looking at.....

***Okay, you need to know. You don't need to pass it on as nothing will come of it and there is not a damned thing anyone can do about it. Don't even hint at it as it will be denied and laughed at.......... USDA is gonna do as little as possible until there is actually a human case in the USA of the nvcjd........ if you want to move this thing along and shake the earth.... then we gotta get the victims families to make sure whoever is doing the autopsy is credible, trustworthy, and a saint with the courage of Joan of Arc........ I am not kidding!!!! so, unless we get a human death from EXACTLY the same form with EXACTLY the same histopath lesions as seen in the UK nvcjd........ forget any action........ it is ALL gonna be sporadic!!! And, if there is a case....... there is gonna be every effort to link it to international travel, international food, etc. etc. etc. etc. etc. They will go so far as to find out if a sex partner had ever traveled to the UK/europe, etc. etc. .... It is gonna be a long, lonely, dangerous twisted journey to the truth. They have all the cards, all the money, and are willing to threaten and carry out those threats.... and this may be their biggest downfall...***

Thanks as always for your help. (Recently had a very startling revelation from a rather senior person in government here.......... knocked me out of my chair........ you must keep pushing. If I was a power person.... I would be demanding that there be at least a million bovine tested as soon as possible and agressively seeking this disease. The big players are coming out of the wood work as there is money to be made!!!

In short: "FIRE AT WILL"!!! for the very dumb.... who's "will"! "Will be the burden to bare if there is any coverup!"

again it was said years ago and it should be taken seriously.... BSE will NEVER be found in the US!

As for the BSE conference call... I think you did agreat service to freedom of information and making some people feign integrity... I find it scary to see that most of the "experts" are employed by the federal government or are supported on the "teat" of federal funds. A scary picture! I hope there is a confidential panel organized by the new government to really investigate this thing.

You need to watch your back........ but keep picking at them....... like a buzzard to the bone... you just may get to the truth!!! (You probably have more support than you know. Too many people are afraid to show you or let anyone else know. I have heard a few things myself... you ask the questions that everyone else is too afraid to ask.)

================================================

END UPDATE...TSS
 

I have often wondered if sporadic FFI, considering there is no link to any family gene, if sporadic FFI could be a by-product of iatrogenic FFI, i.e. friendly fire?

 

ALSO, SINCE the Alabama mad cow atypical BSE was Associated with Prion Protein Gene Mutation (g-h-BSEalabama), and since we do know that these FFI is transmissible, why then is it so far fetched to then believe that the FEED FROM AN ATYPICAL BSE CASE WITH A PRION PROTEIN GENE MUTATION COULD NOT THEN BE PASSED VIA FEED AND IN FOOD TO HUMANS, AS VPSPr PRIONPATHY, AND OR SPORADIC FFI OR SPORADIC GSS ???

 

see ;

 

> Here we report the successful transmission of the disease to experimental animals, placing FFI within the group of infectious cerebral amyloidoses...

 

Letters to Nature Nature 376, 434 - 435 (03 August 2002); doi:10.1038/376434a0

 

 

First experimental transmission of fatal familial insomnia

 

Jun Tateishi*, Paul Brown‡, Tetsuyuki Kitamoto*, Zahirul M. Hoque*, Raymond Roos§, Robert Wollman∥, Larisa Cervenàkovà ‡ & D. Carleton Gajdusek‡

 

* Department of Neuropathology, Neurological Institute, Kyushu University, Fukuoka 812, Japan ‡ Laboratory of CMS Studies, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Mayland 20892, USA Departments of Neurology § and Pathology∥, University of Chicago Medical Center, Chicago, Illinois 60637, USA

 

ORIGINALLY described by Lugaresi et al. in 1986 (ref. 1), fatal familial insomnia (FFI) is a rare inherited neurological disease characterized by the subacute progression of intractable insomnia and other autonomic abnormalities, cerebellar and pyramidal signs, myoclonus and dementia; neuropathologically, the major feature is severe neuronal loss with associated gliosis in the ventral and mediodorsal thalamic nuclei. The disease has been related to the group of spongiform encephalopathies by virtue of the presence of low levels of proteinase-resistant amyloid protein (PrPres) in the brain2á¤-4, and of a pathogenic single-allele mutation at codon 178 of the PRNP gene that encodes PrF68 (refs 2, 5). Here we report the successful transmission of the disease to experimental animals, placing FFI within the group of infectious cerebral amyloidoses.

 

------------------

 

References

 


 

The Lancet, Volume 346, Issue 8974, Pages 569 - 570, 26 August 1995

 

doi:10.1016/S0140-6736(95)91405-6Cite or Link Using DOI Transmission of fatal familial insomnia to laboratory animals Original TextJohn Collinge a, MarkS. Palmer , KatieC.L. Sidle , Ian Gowland , Rosella Medori , James Ironside , Peter Lantos

 





Expedited Publication

 

A subtype of sporadic prion disease mimicking fatal familial insomnia

 

P. Parchi, MD, S. Capellari, MD, S. Chin, MD, PhD, H.B. Schwarz, MD, N.P. Schecter, MD, J.D. Butts, MD, P. Hudkins, MD, D.K. Burns MD, J.M. Powers, MD and P. Gambetti, MD + Show Affiliations Address correspondence and reprint requests to Dr. Pierluigi Gambetti, Division of Neuropathology, Institute of Pathology, Case Western Reserve University, 2085 Adelbert Road, Cleveland, OH 44106.

 

doi: 10.1212/WNL.52.9.1757 Neurology June 1, 1999 vol. 52 no. 9 1757

 

Abstract Full Text Full Text (PDF) Also available: Figures Only PPT Slides of All Figures

 

Abstract

 

Objective: To establish a variant of sporadic prion disease as the sporadic form of fatal familial insomnia (FFI).

 

Background: FFI is a recently described prion disease characterized clinically by severe sleep impairment, dysautonomia, and motor signs, and pathologically by atrophy of thalamic nuclei, especially the medial dorsal and anterior ventral, and of the inferior olive. FFI is linked to the D178N mutation coupled with the methionine codon at position 129 in the prion protein gene (PRNP). It is also identified by the properties of the abnormal prion protein (PrPSc), which has the relative molecular mass of 19 kDa, corresponding to the so-called type 2, and a marked underrepresentation of the unglycosylated form relative to the diglycosylated and monoglycosylated forms.

 

Methods: Clinical, pathologic, PrPSc, and PRNP data from 5 subjects with a sporadic prion disease phenotypically similar to FFI were collected and analyzed.

 

Results: All 5 subjects had a disease clinically similar and histopathologically virtually identical to FFI. PrPSc type 2 was present in all subjects in amount and distribution similar to those of FFI. However, the PrPSc did not show the striking underrepresentation of the unglycosylated isoform of the protein that is characteristic of FFI. Moreover, none of the subjects had the D178N PRNP mutation but all were homozygous for methionine at codon 129.

 

Conclusion: This condition is likely to represent the sporadic form of FFI and the term “sporadic fatal insomnia” is proposed. Received February 23, 1999. Accepted April 3, 1999.

 

 



 

Sunday, March 31, 2013

 

*** Creutzfeldt Jakob Disease CJD worlds youngest documented victim, 11 years old, shall we pray

 


 

 

 HOW TO TURN A POTENTIAL MAD COW VICTIM IN THE USA, INTO A HAPPENSTANCE OF BAD LUCK, A SPONTANEOUS MUTATION FROM NOTHING.

 

OR WAS IT $$$

 

Case report Sporadic fatal insomnia in a young woman: A diagnostic challenge: Case Report

 

Karen M Moody , Lawrence B Schonberger , Ryan A Maddox , Wen-Quan Zou , Laura Cracco and Ignazio Cali

 

BMC Neurology 2011, 11:136doi:10.1186/1471-2377-11-136

 

Published:

 

31 October 2011

 

Abstract (provisional)

 

Background

 

Sporadic fatal insomnia (sFI) and fatal familial insomnia (FFI) are rare human prion diseases.

 

Case presentation

 

We report a case of a 33-year-old female who died of a prion disease for whom the diagnosis of sFI or FFI was not considered clinically. Following death of this patient, an interview with a close family member indicated the patient's illness included a major change in her sleep pattern, corroborating the reported autopsy diagnosis of sFI. Genetic tests identified no prion protein (PrP) gene mutation, but neuropathological examination and molecular study showed protease-resistant PrP (PrPres) in several brain regions and severe atrophy of the anterior-ventral and medial-dorsal thalamic nuclei similar to that described in FFI.

 

Conclusions

 

In patients with suspected prion disease, a characteristic change in sleep pattern can be an important clinical clue for identifying sFI or FFI; polysomnography (PSG), genetic analysis, and nuclear imaging may aid in diagnosis.

 

snip...

 

Case presentation

 

Clinical findings In February 2007, the Centers for Disease Control and Prevention (CDC) and the National Prion Disease Pathology Surveillance Center (NPDPSC) notified the Texas Department of State Health Services (DSHS) of a 32-year-old woman with an 18-month history of progressive neurological symptoms suggestive of CJD. (Table 1) Based on the medical record and her neurologist, her illness began in August 2005 with attention deficits and progressive memory loss. In June 2006, she demonstrated anisocoria and bizarre behavior, including talking incoherently to herself, and she was then referred to psychiatry. On a mini-mental state examination, she scored abnormally low in the measure of attention and calculation and she had reduced ability to repeat the names of three unrelated objects [14]. Later in 2006 she was described as being in constant motion, having unfocused hand gestures, and continued difficulty with ambulation. She was reported as alert, but confused, sad, and having difficulty with her thought process. Physicians caring for the case patient discussed the possibility of several diagnoses such as viral encephalopathy, paranoid schizophrenia, and subacute sclerosing panencephalitis, yet the overall etiology remained unclear. By February 2007, the patient was unable to ambulate and became bed-bound. She continued to demonstrate bizarre behavior, inability to follow commands, and unintelligible speech. The patient expired in June 2007, 22 months after the onset of illness.

 

Over the course of her illness, she had EEGs, magnetic resonance imaging (MRI) studies, and cerebrospinal fluid (CSF) tests. The EEG study performed in July 2006 showed generalized slowing with bilateral periodic lateralized epileptiform discharges. A second EEG performed two to three weeks later was unsuccessful due to excessive movements of the patient. In April 2006, an MRI study was negative for intracranial abnormalities. Another MRI study was completed in February 2007 and it showed supratentorial parenchymal atrophy with no other acute intracranial findings. CSF studies performed in March 2007 were normal, including the amount of the 14-3-3 protein determined.

 

Because of the age of the patient and the potential for variant or iatrogenic CJD, in July 2007 an investigator from the DSHS (KMM) interviewed a family member to obtain additional information about the patient's travel history, past medical history, and the symptoms of the present illness. The patient had a history of travel outside the continental United States to Puerto Rico during 1995-96 where she had lived approximately one year. Her surgical history included two back surgeries for internal disc disruption and degenerative disc disease. An anterior lumbar discectomy with interbody fusion at L4-5 was performed in November 2000 utilizing cadaver donated bone and in August 2001 another fusion was performed at L5-S1 utilizing autologous bone. The donor of cadaver bone was pre-screened minimizing the possibility of iatrogenic transmission. There was no familial history of progressive neurological disease or dementia-like illness. The family member also confirmed the clinical history including the onset in August 2005 of progressive memory loss and, in February 2006, bizarre behavior that included the patient's sitting in a chair for hours making noises that progressively got louder.

 

Following preliminary autopsy results, the NPDPSC requested the DSHS re-interview the family to ask specifically about the patient's pattern of sleep. When questioned about insomnia, the family member recalled that the patient had experienced disturbed sleep at the time of her disease onset. The family member also reported that the patient's sleep pattern progressively deteriorated throughout her illness. Some nights, for example, the patient did not sleep. On other nights when she did appear to be sleeping, her sleep was intermittent. During nights that the patient did not sleep, she would roam the house at all hours, unable to calm down. By August of 2006, four hours was the maximum amount of sleep the patient would get in one stretch and at times she would go two to three days without sleep. Medications were prescribed to help her sleep but they were not beneficial.

 

Genetic analysis Sequencing of the PrP gene open reading frame revealed methionine homozygosity at codon 129, with no pathogenic mutation.

 

snip...

 

see full text ;

 


 

 ===================

 

Clinical findings In February 2007, the Centers for Disease Control and Prevention (CDC) and the National Prion Disease Pathology Surveillance Center (NPDPSC) notified the Texas Department of State Health Services (DSHS) of a 32-year-old woman with an 18-month history of progressive neurological symptoms suggestive of CJD. (Table 1) Based on the medical record and her neurologist, her illness began in August 2005 with attention deficits and progressive memory loss. In June 2006, she demonstrated anisocoria and bizarre behavior, including talking incoherently to herself, and she was then referred to psychiatry.

 

=====================

 

 AND THAT MY FRIENDS, IS HOW YOU EXPLAIN SOMETHING AWAY INTO NOTHING. IT'S THE USDA ET AL MAD COW WAY $$$

 

how many times have we seen this happen? time and time again.

 

sporadic FFI or nvCJD Texas style ???

 

 DEEP THROAT TO TSS 2000-2001 (take these old snips of emails with how ever many grains of salt you wish. ...tss)

 

The most frightening thing I have read all day is the report of Gambetti's finding of a new strain of sporadic cjd in young people...Dear God, what in the name of all that is holy is that!!! If the US has different strains of scrapie.....why????than the UK...then would the same mechanisms that make different strains of scrapie here make different strains of BSE...if the patterns are different in sheep and mice for scrapie.....could not the BSE be different in the cattle, in the mink, in the humans.......I really think the slides or tissues and everything from these young people with the new strain of sporadic cjd should be put up to be analyzed by many, many experts in cjd........bse.....scrapie Scrape the damn slide and put it into mice.....wait.....chop up the mouse brain and and spinal cord........put into some more mice.....dammit amplify the thing and start the damned research.....This is NOT rocket science...we need to use what we know and get off our butts and move....the whining about how long everything takes.....well it takes a whole lot longer if you whine for a year and then start the research!!! Not sure where I read this but it was a recent press release or something like that: I thought I would fall out of my chair when I read about how there was no worry about infectivity from a histopath slide or tissues because they are preserved in formic acid, or formalin or formaldehyde.....for God's sake........ Ask any pathologist in the UK what the brain tissues in the formalin looks like after a year.......it is a big fat sponge...the agent continues to eat the brain ......you can't make slides anymore because the agent has never stopped........and the old slides that are stained with Hemolysin and Eosin......they get holier and holier and degenerate and continue...what you looked at 6 months ago is not there........Gambetti better be photographing every damned thing he is looking at.....

 

Okay, you need to know. You don't need to pass it on as nothing will come of it and there is not a damned thing anyone can do about it. Don't even hint at it as it will be denied and laughed at.......... USDA is gonna do as little as possible until there is actually a human case in the USA of the nvcjd........if you want to move this thing along and shake the earth....then we gotta get the victims families to make sure whoever is doing the autopsy is credible, trustworthy, and a saint with the courage of Joan of Arc........I am not kidding!!!! so, unless we get a human death from EXACTLY the same form with EXACTLY the same histopath lesions as seen in the UK nvcjd........forget any action........it is ALL gonna be sporadic!!!

 

And, if there is a case.......there is gonna be every effort to link it to international travel, international food, etc. etc. etc. etc. etc. They will go so far as to find out if a sex partner had ever traveled to the UK/europe, etc. etc. .... It is gonna be a long, lonely, dangerous twisted journey to the truth. They have all the cards, all the money, and are willing to threaten and carry out those threats....and this may be their biggest downfall...

 

Thanks as always for your help. (Recently had a very startling revelation from a rather senior person in government here..........knocked me out of my chair........you must keep pushing. If I was a power person....I would be demanding that there be a least a million bovine tested as soon as possible and agressively seeking this disease. The big players are coming out of the woodwork as there is money to be made!!! In short: "FIRE AT WILL"!!! for the very dumb....who's "will"! "Will be the burden to bare if there is any coverup!"

 

again it was said years ago and it should be taken seriously....BSE will NEVER be found in the US! As for the BSE conference call...I think you did a great service to freedom of information and making some people feign integrity...I find it scary to see that most of the "experts" are employed by the federal government or are supported on the "teat" of federal funds. A scary picture! I hope there is a confidential panel organized by the new government to really investigate this thing.

 

You need to watch your back........but keep picking at them.......like a buzzard to the bone...you just may get to the truth!!! (You probably have more support than you know. Too many people are afraid to show you or let anyone else know. I have heard a few things myself... you ask the questions that everyone else is too afraid to ask.)

 

END...TSS

 

nvCJD Clinical course

 

The clinical course of disease in the ten patients was distinct from that usually seen in sporadic CJD (table 2). Nine had behavioural changes as an early clinical feature and were referred to a psychiatrist. In four patients, an early symptom was dysaesthesiae and in another, pain in the feet persisted throughout the illness. Nine patients developed ataxia early in the course of the disease. While all patients developed progressive dementia, in only two was memory impairment part of initial clinical presentation. Seven of the patients developed myoclonus, often late in the course of the disease, and three had choreoathetosis. None of the cases had the electroencephalographic (EEG) features usually associated with CJD.

 


 


 

 

LET'S take a closer look at this new prionpathy or prionopathy, and then let's look at the g-h-BSEalabama mad cow.

 

This new prionopathy in humans? the genetic makeup is IDENTICAL to the g-h-BSEalabama mad cow, the only _documented_ mad cow in the world to date like this, ......wait, it get's better. this new prionpathy is killing young and old humans, with LONG DURATION from onset of symptoms to death, and the symptoms are very similar to nvCJD victims, OH, and the plaques are very similar in some cases too, bbbut, it's not related to the g-h-BSEalabama cow, WAIT NOW, it gets even better, the new human prionpathy that they claim is a genetic TSE, has no relation to any gene mutation in that family. daaa, ya think it could be related to that mad cow with the same genetic make-up ??? there were literally tons and tons of banned mad cow protein in Alabama in commerce, and none of it transmitted to cows, and the cows to humans there from ??? r i g h t $$$

 

ALABAMA MAD COW g-h-BSEalabama

 

In this study, we identified a novel mutation in the bovine prion protein gene (Prnp), called E211K, of a confirmed BSE positive cow from Alabama, United States of America. This mutation is identical to the E200K pathogenic mutation found in humans with a genetic form of CJD. This finding represents the first report of a confirmed case of BSE with a potential pathogenic mutation within the bovine Prnp gene. We hypothesize that the bovine Prnp E211K mutation most likely has caused BSE in "the approximately 10-year-old cow" carrying the E221K mutation.

 


 


 

 

Saturday, August 14, 2010

 

BSE Case Associated with Prion Protein Gene Mutation (g-h-BSEalabama) and VPSPr PRIONPATHY

 

(see mad cow feed in COMMERCE IN ALABAMA...TSS)

 


 

 

her healthy calf also carried the mutation (J. A. Richt and S. M. Hall PLoS Pathog. 4, e1000156; 2008).

 

This raises the possibility that the disease could occasionally be genetic in origin. Indeed, the report of the UK BSE Inquiry in 2000 suggested that the UK epidemic had most likely originated from such a mutation and argued against the scrapierelated assumption. Such rare potential pathogenic PRNP mutations could occur in countries at present considered to be free of BSE, such as Australia and New Zealand. So it is important to maintain strict surveillance for BSE in cattle, with rigorous enforcement of the ruminant feed ban (many countries still feed ruminant proteins to pigs). Removal of specified risk material, such as brain and spinal cord, from cattle at slaughter prevents infected material from entering the human food chain. Routine genetic screening of cattle for PRNP mutations, which is now available, could provide additional data on the risk to the public. Because the point mutation identified in the Alabama animals is identical to that responsible for the commonest type of familial (genetic) CJD in humans, it is possible that the resulting infective prion protein might cross the bovine-human species barrier more easily. Patients with vCJD continue to be identified. The fact that this is happening less often should not lead to relaxation of the controls necessary to prevent future outbreaks.

 

Malcolm A. Ferguson-Smith Cambridge University Department of Veterinary Medicine, Madingley Road, Cambridge CB3 0ES, UK e-mail: maf12@cam.ac.uk Jürgen A. Richt College of Veterinary Medicine, Kansas State University, K224B Mosier Hall, Manhattan, Kansas 66506-5601, USA

 

NATURE|Vol 457|26 February 2009

 


 

 

P.9.21

 

Molecular characterization of BSE in Canada

 

Jianmin Yang1, Sandor Dudas2, Catherine Graham2, Markus Czub3, Tim McAllister1, Stefanie Czub1 1Agriculture and Agri-Food Canada Research Centre, Canada; 2National and OIE BSE Reference Laboratory, Canada; 3University of Calgary, Canada

 

Background: Three BSE types (classical and two atypical) have been identified on the basis of molecular characteristics of the misfolded protein associated with the disease. To date, each of these three types have been detected in Canadian cattle.

 

Objectives: This study was conducted to further characterize the 16 Canadian BSE cases based on the biochemical properties of there associated PrPres. Methods: Immuno-reactivity, molecular weight, glycoform profiles and relative proteinase K sensitivity of the PrPres from each of the 16 confirmed Canadian BSE cases was determined using modified Western blot analysis.

 

Results: Fourteen of the 16 Canadian BSE cases were C type, 1 was H type and 1 was L type. The Canadian H and L-type BSE cases exhibited size shifts and changes in glycosylation similar to other atypical BSE cases. PK digestion under mild and stringent conditions revealed a reduced protease resistance of the atypical cases compared to the C-type cases. N terminal- specific antibodies bound to PrPres from H type but not from C or L type. The C-terminal-specific antibodies resulted in a shift in the glycoform profile and detected a fourth band in the Canadian H-type BSE.

 

Discussion: The C, L and H type BSE cases in Canada exhibit molecular characteristics similar to those described for classical and atypical BSE cases from Europe and Japan. This supports the theory that the importation of BSE contaminated feedstuff is the source of C-type BSE in Canada.

 

*** It also suggests a similar cause or source for atypical BSE in these countries.

 


 

what about that ALABAMA MAD COW, AND MAD COW FEED THERE FROM IN THAT STATE ???

 

Saturday, August 14, 2010

 

BSE Case Associated with Prion Protein Gene Mutation (g-h-BSEalabama) and VPSPr PRIONPATHY

 

*** (see mad cow feed in COMMERCE IN ALABAMA...TSS)

 

BANNED MAD COW FEED IN COMMERCE IN ALABAMA

 

Date: September 6, 2006 at 7:58 am PST PRODUCT

 

a) EVSRC Custom dairy feed, Recall # V-130-6;

 

b) Performance Chick Starter, Recall # V-131-6;

 

c) Performance Quail Grower, Recall # V-132-6;

 

d) Performance Pheasant Finisher, Recall # V-133-6.

 

CODE None RECALLING FIRM/MANUFACTURER Donaldson & Hasenbein/dba J&R Feed Service, Inc., Cullman, AL, by telephone on June 23, 2006 and by letter dated July 19, 2006. Firm initiated recall is complete.

 

REASON

 

Dairy and poultry feeds were possibly contaminated with ruminant based protein.

 

VOLUME OF PRODUCT IN COMMERCE 477.72 tons

 

DISTRIBUTION AL

 

______________________________

 


 

PRODUCT Bulk custom dairy pre-mixes,

 

Recall # V-120-6 CODE None RECALLING FIRM/MANUFACTURER Ware Milling Inc., Houston, MS, by telephone on June 23, 2006. Firm initiated recall is complete. REASON Possible contamination of dairy animal feeds with ruminant derived meat and bone meal.

 

VOLUME OF PRODUCT IN COMMERCE 350 tons

 

DISTRIBUTION AL and MS

 

______________________________

 

PRODUCT

 

a) Tucker Milling, LLC Tm 32% Sinking Fish Grower, #2680-Pellet, 50 lb. bags, Recall # V-121-6;

 

b) Tucker Milling, LLC #31120, Game Bird Breeder Pellet, 50 lb. bags, Recall # V-122-6;

 

c) Tucker Milling, LLC #31232 Game Bird Grower, 50 lb. bags, Recall # V-123-6;

 

d) Tucker Milling, LLC 31227-Crumble, Game Bird Starter, BMD Medicated, 50 lb bags, Recall # V-124-6;

 

e) Tucker Milling, LLC #31120, Game Bird Breeder, 50 lb bags, Recall # V-125-6;

 

f) Tucker Milling, LLC #30230, 30 % Turkey Starter, 50 lb bags, Recall # V-126-6;

 

g) Tucker Milling, LLC #30116, TM Broiler Finisher, 50 lb bags, Recall # V-127-6

 

CODE All products manufactured from 02/01/2005 until 06/20/2006 RECALLING FIRM/MANUFACTURER Recalling Firm: Tucker Milling LLC, Guntersville, AL, by telephone and visit on June 20, 2006, and by letter on June 23, 2006. Manufacturer: H. J. Baker and Brothers Inc., Stamford, CT. Firm initiated recall is ongoing.

 

REASON Poultry and fish feeds which were possibly contaminated with ruminant based protein were not labeled as "Do not feed to ruminants".

 

VOLUME OF PRODUCT IN COMMERCE 7,541-50 lb bags

 

DISTRIBUTION AL, GA, MS, and TN

 

END OF ENFORCEMENT REPORT FOR AUGUST 9, 2006

 

###

 


 

Subject: MAD COW FEED RECALL AL AND FL VOLUME OF PRODUCT IN COMMERCE 125 TONS Products manufactured from 02/01/2005 until 06/06/2006

 

Date: August 6, 2006 at 6:16 pm PST PRODUCT

 

a) CO-OP 32% Sinking Catfish, Recall # V-100-6;

 

b) Performance Sheep Pell W/Decox/A/N, medicated, net wt. 50 lbs, Recall # V-101-6;

 

c) Pro 40% Swine Conc Meal -- 50 lb, Recall # V-102-6;

 

d) CO-OP 32% Sinking Catfish Food Medicated, Recall # V-103-6;

 

e) "Big Jim's" BBB Deer Ration, Big Buck Blend, Recall # V-104-6;

 

f) CO-OP 40% Hog Supplement Medicated Pelleted, Tylosin 100 grams/ton, 50 lb. bag, Recall # V-105-6;

 

g) Pig Starter Pell II, 18% W/MCDX Medicated 282020, Carbadox -- 0.0055%, Recall # V-106-6;

 

h) CO-OP STARTER-GROWER CRUMBLES, Complete Feed for Chickens from Hatch to 20 Weeks, Medicated, Bacitracin Methylene Disalicylate, 25 and 50 Lbs, Recall # V-107-6;

 

i) CO-OP LAYING PELLETS, Complete Feed for Laying Chickens, Recall # 108-6;

 

j) CO-OP LAYING CRUMBLES, Recall # V-109-6;

 

k) CO-OP QUAIL FLIGHT CONDITIONER MEDICATED, net wt 50 Lbs, Recall # V-110-6;

 

l) CO-OP QUAIL STARTER MEDICATED, Net Wt. 50 Lbs, Recall # V-111-6;

 

m) CO-OP QUAIL GROWER MEDICATED, 50 Lbs, Recall # V-112-6 CODE

 

Product manufactured from 02/01/2005 until 06/06/2006

 

RECALLING FIRM/MANUFACTURER Alabama Farmers Cooperative, Inc., Decatur, AL, by telephone, fax, email and visit on June 9, 2006. FDA initiated recall is complete.

 

REASON Animal and fish feeds which were possibly contaminated with ruminant based protein not labeled as "Do not feed to ruminants".

 

VOLUME OF PRODUCT IN COMMERCE 125 tons

 

DISTRIBUTION AL and FL

 

END OF ENFORCEMENT REPORT FOR AUGUST 2, 2006

 

###

 


 

MAD COW FEED RECALL USA EQUALS 10,878.06 TONS NATIONWIDE Sun Jul 16, 2006 09:22 71.248.128.67

 

RECALLS AND FIELD CORRECTIONS: VETERINARY MEDICINE -- CLASS II

 

______________________________

 

PRODUCT

 

a) PRO-LAK, bulk weight, Protein Concentrate for Lactating Dairy Animals, Recall # V-079-6;

 

b) ProAmino II, FOR PREFRESH AND LACTATING COWS, net weight 50lb (22.6 kg), Recall # V-080-6;

 

c) PRO-PAK, MARINE & ANIMAL PROTEIN CONCENTRATE FOR USE IN ANIMAL FEED, Recall # V-081-6;

 

d) Feather Meal, Recall # V-082-6 CODE

 

a) Bulk

 

b) None

 

c) Bulk

 

d) Bulk

 

RECALLING FIRM/MANUFACTURER H. J. Baker & Bro., Inc., Albertville, AL, by telephone on June 15, 2006 and by press release on June 16, 2006. Firm initiated recall is ongoing.

 

REASON

 

Possible contamination of animal feeds with ruminent derived meat and bone meal.

 

VOLUME OF PRODUCT IN COMMERCE 10,878.06 tons

 

DISTRIBUTION Nationwide

 

END OF ENFORCEMENT REPORT FOR July 12, 2006

 

###

 


 

2007

 

10,000,000+ LBS. of PROHIBITED BANNED MAD COW FEED I.E. BLOOD LACED MBM IN COMMERCE USA 2007

 

Date: March 21, 2007 at 2:27 pm PST

 

RECALLS AND FIELD CORRECTIONS: VETERINARY MEDICINES -- CLASS II

 

PRODUCT

 

Bulk cattle feed made with recalled Darling's 85% Blood Meal, Flash Dried, Recall # V-024-2007

 

CODE

 

Cattle feed delivered between 01/12/2007 and 01/26/2007

 

RECALLING FIRM/MANUFACTURER

 

Pfeiffer, Arno, Inc, Greenbush, WI. by conversation on February 5, 2007.

 

Firm initiated recall is ongoing.

 

REASON

 

Blood meal used to make cattle feed was recalled because it was cross- contaminated with prohibited bovine meat and bone meal that had been manufactured on common equipment and labeling did not bear cautionary BSE statement.

 

VOLUME OF PRODUCT IN COMMERCE

 

42,090 lbs.

 

DISTRIBUTION

 

WI

 

___________________________________

 

PRODUCT

 

Custom dairy premix products:

 

MNM ALL PURPOSE Pellet, HILLSIDE/CDL Prot- Buffer Meal, LEE, M.-CLOSE UP PX Pellet, HIGH DESERT/ GHC LACT Meal, TATARKA, M CUST PROT Meal, SUNRIDGE/CDL PROTEIN Blend, LOURENZO, K PVM DAIRY Meal, DOUBLE B DAIRY/GHC LAC Mineral, WEST PIONT/GHC CLOSEUP Mineral, WEST POINT/GHC LACT Meal, JENKS, J/COMPASS PROTEIN Meal, COPPINI - 8# SPECIAL DAIRY Mix, GULICK, L-LACT Meal (Bulk), TRIPLE J - PROTEIN/LACTATION, ROCK CREEK/GHC MILK Mineral, BETTENCOURT/GHC S.SIDE MK-MN, BETTENCOURT #1/GHC MILK MINR, V&C DAIRY/GHC LACT Meal, VEENSTRA, F/GHC LACT Meal, SMUTNY, A- BYPASS ML W/SMARTA, Recall # V-025-2007

 

CODE

 

The firm does not utilize a code - only shipping documentation with commodity and weights identified.

 

RECALLING FIRM/MANUFACTURER

 

Rangen, Inc, Buhl, ID, by letters on February 13 and 14, 2007. Firm initiated recall is complete.

 

REASON

 

Products manufactured from bulk feed containing blood meal that was cross contaminated with prohibited meat and bone meal and the labeling did not bear cautionary BSE statement.

 

VOLUME OF PRODUCT IN COMMERCE

 

9,997,976 lbs.

 

DISTRIBUTION

 

ID and NV

 

END OF ENFORCEMENT REPORT FOR MARCH 21, 2007

 


 

Saturday, August 4, 2012

 

Final Feed Investigation Summary - California BSE Case - July 2012

 


 


 

What irks many scientists is the USDA’s April 25 statement that the rare disease is “not generally associated with an animal consuming infected feed.”

 

The USDA’s conclusion is a “gross oversimplification,” said Dr. Paul Brown, one of the world’s experts on this type of disease who retired recently from the National Institutes of Health.

 

"(The agency) has no foundation on which to base that statement.”

 

“We can’t say it’s not feed related,” agreed Dr. Linda Detwiler, an official with the USDA during the Clinton Administration now at Mississippi State.

 

In the May 1 email to me, USDA’s Cole backed off a bit. “No one knows the origins of atypical cases of BSE,” she said

 

Saturday, May 26, 2012

 

Are USDA assurances on mad cow case 'gross oversimplification'?

 


 


 

 Sunday, December 15, 2013

 

*** FDA PART 589 -- SUBSTANCES PROHIBITED FROM USE IN ANIMAL FOOD OR FEED VIOLATIONS OFFICIAL ACTION INDICATED OIA UPDATE DECEMBER 2013 UPDATE

 


 

Thursday, June 23, 2011

 

Experimental H-type bovine spongiform encephalopathy characterized by plaques and glial- and stellate-type prion protein deposits

 


 

 Thursday, July 21, 2011

 

A Second Case of Gerstmann-Sträussler-Scheinker Disease Linked to the G131V Mutation in the Prion Protein Gene in a Dutch Patient Journal of Neuropathology & Experimental Neurology:

 

August 2011 - Volume 70 - Issue 8 - pp 698-702

 


 

 PLEASE NOTE *

 

Over the next 8-10 weeks, approximately 40% of all the adult mink on the farm died from TME.

 

snip...

 

The rancher was a ''dead stock'' feeder using mostly (> 95 %) downer or dead dairy cattle...

 


 

 Saturday, June 25, 2011

 

Transmissibility of BSE-L and Cattle-Adapted TME Prion Strain to Cynomolgus Macaque

 

"BSE-L in North America may have existed for decades"

 


 

 Sunday, June 26, 2011

 

Risk Analysis of Low-Dose Prion Exposures in Cynomolgus Macaque

 


 

 Monday, May 11, 2009

 

Rare BSE mutation raises concerns over risks to public health

 


 

 Wednesday, July 28, 2010

 

Atypical prion proteins and IBNC in cattle DEFRA project code SE1796 FOIA Final report

 


 

 IBNC

 

"All of the 15 cattle tested showed that the brains had abnormally accumulated prion protein."

 

Saturday, February 28, 2009

 

NEW RESULTS ON IDIOPATHIC BRAINSTEM NEURONAL CHROMATOLYSIS "All of the 15 cattle tested showed that the brains had abnormally accumulated PrP" 2009

 

SEAC 102/2

 


 

 2009 UPDATE ON ALABAMA AND TEXAS MAD COWS 2005 and 2006

 


 

 Friday, May 13,

 

2011 EFSA Joint Scientific Opinion on any possible epidemiological or molecular association between TSEs in animals and humans

 


 

 Sunday, May 01, 2011

 

STUDY OF ATYPICAL BSE 2010 Annual Report May 2011

 


 

 Tuesday, November 08, 2011

 

Can Mortality Data Provide Reliable Indicators for Creutzfeldt-Jakob Disease Surveillance? A Study in France from 2000 to 2008 Vol. 37, No. 3-4, 2011

 

Original Paper

 

Conclusions:These findings raise doubt about the possibility of a reliable CJD surveillance only based on mortality data.

 


 

 Friday, November 04, 2011

 

Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study Research article

 


 

 Monday, September 26, 2011

 

Variably Protease-Sensitive Prionopathy, Prionpathy, Prionopathy, FFI, GSS, gCJD, hvCJD, sCJD, TSE, PRION, update 2011

 


 

 Monday, June 27, 2011

 

Comparison of Sheep Nor98 with Human Variably Protease-Sensitive Prionopathy and Gerstmann-Sträussler-Scheinker Disease

 


 

 Thursday, July 10, 2008

 

A New Prionopathy update July 10, 2008

 


 

 Thursday, July 10, 2008

 

A Novel Human Disease with Abnormal Prion Protein Sensitive to Protease update July 10, 2008 Friday, June 20, 2008

 


 

 Sunday, August 10, 2008

 

A New Prionopathy OR more of the same old BSe and sporadic CJD

 


 

 Sunday, August 24, 2008

 

Sporadic Fatal Insomnia with Unusual Biochemical and Neuropathological Findings

 


 

 Here we go folks. AS predicted. THIS JUST OUT ! as i predicted, more BSe. ...

 

Tuesday, August 03, 2010

 

Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein

 


 

 Monday, August 9, 2010

 

Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein or just more PRIONBALONEY ?

 

snip...see full text ;

 


 


 

 O.K. let's compare some recent cases of this prionpathy in other countries besides Gambetti's first 10 recently, that he claims is a spontaneous event, from a genetic disorder, that is not genetic, but sporadic, that is related to no animal TSE in North America, or the world. ...

 


 


 


 


 

 Sunday, August 09, 2009

 

CJD...Straight talk with...James Ironside...and...Terry Singeltary... 2009

 


 

 Tuesday, August 18, 2009

 

BSE-The Untold Story - joe gibbs and singeltary 1999 - 2009

 


 

 2011

 

EFSA Journal 2011 The European Response to BSE: A Success Story

 

This is an interesting editorial about the Mad Cow Disease debacle, and it's ramifications that will continue to play out for decades to come ;

 

Monday, October 10, 2011

 

EFSA Journal 2011 The European Response to BSE: A Success Story

 

snip...

 

EFSA and the European Centre for Disease Prevention and Control (ECDC) recently delivered a scientific opinion on any possible epidemiological or molecular association between TSEs in animals and humans (EFSA Panel on Biological Hazards (BIOHAZ) and ECDC, 2011). This opinion confirmed Classical BSE prions as the only TSE agents demonstrated to be zoonotic so far but the possibility that a small proportion of human cases so far classified as "sporadic" CJD are of zoonotic origin could not be excluded. Moreover, transmission experiments to non-human primates suggest that some TSE agents in addition to Classical BSE prions in cattle (namely L-type Atypical BSE, Classical BSE in sheep, transmissible mink encephalopathy (TME) and chronic wasting disease (CWD) agents) might have zoonotic potential.

 

snip...

 


 


 

see follow-up here about North America BSE Mad Cow TSE prion risk factors, and the ever emerging strains of Transmissible Spongiform Encephalopathy in many species here in the USA, including humans ;

 


 

 Monday, September 26, 2011

 

L-BSE BASE prion and atypical sporadic CJD

 


 

 Thursday, August 4, 2011

 

Terry Singeltary Sr. on the Creutzfeldt-Jakob Disease Public Health Crisis, Date aired: 27 Jun 2011

 


 

 

 

Please notice where sporadic CJD cases in 1996 went from 28 cases, to 215 cases in 2009, the highest recorded year to date. sporadic CJD is on a steady rise, and has been since 1996.

 

I also urge you to again notice these disturbing factors in lines 5 and 6 ;

 

5 Includes 18 cases in which the diagnosis is pending, and 18 inconclusive cases;

 

6 Includes 23 (22 from 2010) cases with type determination pending in which the diagnosis of vCJD has been excluded.

 

 ========end=====tss=====2011

 

 PPS POLITICAL PRION SCIENCE $$$

 

Creutzfeldt-Jakob Disease Surveillance in Texas

 


 

 Sunday, July 11, 2010

 

CJD or prion disease 2 CASES McLennan County Texas population 230,213 both cases in their 40s

 


 


 

 see the continuing rise of sporadic CJD in Texas here ;

 


 

 Saturday, March 5, 2011

 

MAD COW ATYPICAL CJD PRION TSE CASES WITH CLASSIFICATIONS PENDING ON THE RISE IN NORTH AMERICA

 


 

 Sunday, August 21, 2011

 

The British disease, or a disease gone global, The TSE Prion Disease

 

(see video here)

 


 

 U.S.A. HIDING MAD COW DISEASE VICTIMS AS SPORADIC CJD ?

 

(see video at bottom)

 


 

 Sunday, September 6, 2009

 

MAD COW USA 1997

 

(SEE SECRET VIDEO)

 


 

 Tuesday, November 01, 2011

 

Could we face the return of CJD? Experts fear it may lie dormant in thousands

 


 

 MAD COW DISEASE, TEXAS STYLE

 


 

 Case report Sporadic fatal insomnia in a young woman: A diagnostic challenge: Case Report TEXAS

 

HOW TO TURN A POTENTIAL MAD COW VICTIM IN THE USA, INTO A HAPPENSTANCE OF BAD LUCK, A SPONTANEOUS MUTATION FROM NOTHING.

 

OR WAS IT $$$

 


 

 

 

2/12/2014

 

*********

 

Response from Linda Detwiler, Assistant Director of the Center for Public and Corporate Veterinary Medicine (CPCVM) at the Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland:

 

I respectfully disagree with your assessment that the current BSE SRM requirements are not necessary. Unlike your cute hound analogy where you have definitive proof of zero risk, one cannot say the same about BSE. I could provide > 5 pages of scientific justification for these requirements but I am limited by the word count.

 

So in a nutshell:

 

• We do not truly know or understand the “real” risk to the public in regards to vCJD as caused by classical BSE and any risk that may be caused by atypical BSE.

 

• Per results of the UK’s appendix survey, it appears that humans may be susceptible to infection with the BSE agent at doses below what was previously considered. Currently the central prevalence estimate of vCJD in the UK is very close to 1 in 2,000 in the age cohort tested.

 

• The UK has substantial evidence of “subclinical” vCJD and it is not known whether these people will ever develop the disease and/or if they are a risk to the blood or organ supply.

 

• We have less of an understanding of atypical BSE and its potential risk to humans. All 3 native born cases in the US were atypical. The US surveillance system is not intended to detect and eliminate such cases from the food supply, hence after each case was reported, the government reassured the public that the SRM bans were protective.

 

• In March 2013, APHIS will begin allowing the importation of certain live bovines and bovine products from other countries. The risk to the US public is not limited to the US system alone.

 


 

SNIP...SEE FULL TEXT AND MORE HERE ;

 

Thursday, February 20, 2014

 

Unnecessary precautions BSE MAD COW DISEASE Dr. William James FSIS VS Dr. Linda Detwiler 2014

 


 

Monday, February 3, 2014

 

*** Evaluation of the zoonotic potential of transmissible mink encephalopathy TSE Prion disease

 

Research Project: TRANSMISSION, DIFFERENTIATION, AND PATHOBIOLOGY OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES

 


 

 Sunday, February 16, 2014

 

Recycling collection to benefit young mother with rare, terminal disease

 

Buy This Photo Photo 1 of 1 | Zoom Photo + Top Photo Sandi Kennedy, shown here with her oldest son, is now home with family and the community is rallying around her. Courtesy photo By Staff reports February 14, 2014 3:21 PM KENNEBUNK - The CAN DO program at the Kennebunk Transfer Station will spend the next two months collecting cans and bottles to help the family of Sandi Kennedy, a young Kennebunk mother struck by a rare, fatal disease.

 

"Drop off bottles and cans with a redemption value (Maine State deposit only) at the Transfer Station on Sea Road," said CAN DO organizer Tom Couming. "This will continue for at least two months."

 

Doctors have diagnosed Kennedy, a 38-year-old wife and mom of four young children ages 2 to 9, with Creutzfeldt-Jakob Disease, an incurable neurological disorder, part of a family known as prion diseases.

 

Kennedy is now at her home in Kennebunk, surrounded by family, and will be on hospice care as doctors have given her a short time to live.

 

Friends and family members have created a page on YouCaring.com to support the Kennedy family. Visit youcaring.com and search for "Hope for Sandi." One hundred percent of any money raised through the page will benefit the Kennedys.

 


 

Sunday, August 09, 2009

 

CJD...Straight talk with...James Ironside...and...Terry Singeltary... 2009

 


 


 


 

Friday, January 10, 2014

 

vpspr, sgss, sffi, TSE, an iatrogenic by-product of gss, ffi, familial type prion disease, what it ???

 


 

Monday, February 03, 2014

 

CREUTZFELDT-JAKOB DISEASE T.S.E. PRION U.K. UPDATE As at 3rd February 2014

 


 

WHAT about the sporadic CJD TSE proteins ?

 

WE now know that some cases of sporadic CJD are linked to atypical BSE and atypical Scrapie, so why are not MORE concerned about the sporadic CJD, and all it’s sub-types $$$

 

Creutzfeldt-Jakob Disease CJD cases rising North America updated report August 2013

 

*** Creutzfeldt-Jakob Disease CJD cases rising North America with Canada seeing an extreme increase of 48% between 2008 and 2010 ***

 


 

Sunday, October 13, 2013

 

*** CJD TSE Prion Disease Cases in Texas by Year, 2003-2012

 


 

Sunday, January 19, 2014

 

National Prion Disease Pathology Surveillance Center Cases Examined1 as of January 8, 2014

 


 

Wednesday, December 11, 2013

 

*** Detection of Infectivity in Blood of Persons with Variant and Sporadic Creutzfeldt-Jakob Disease ***

 


 

Friday, February 14, 2014

 

Creutzfeldt-Jakob disease (CJD) biannual update (February 2014), with briefing on novel human prion disease National CJD Research and Surveillance Unit NCJDRSU

 


 

TSS

Thursday, December 23, 2010

Atypical Prion Protein Conformation in Familial Prion Disease with PRNP P105T Mutation

RESEARCH A R T I C L E bpa_439 1..6

Atypical Prion Protein Conformation in Familial Prion Disease with PRNP P105T Mutation

Magdalini Polymenidou1,2,*; Stefan Prokop1,3,*; Hans H. Jung4; Ekkehard Hewer1; David Peretz5,6;

Rita Moos1; Markus Tolnay1,7; Adriano Aguzzi1

4 Department of Neurology, 1 Institute of Neuropathology, University Hospital Zurich and 7 Basel, Switzerland.

5 Novartis Vaccines and Diagnostics, Emeryville, Calif.

2 Current address: Department of Cellular and Molecular Medicine, University of California at San Diego, Calif.

3 Current address: Department of Neuropathology, Charité—Universitätsmedizin Berlin, Germany.

6 Current address: Tethys Bioscience, Emeryville, Calif.


Abstract

Protease-resistant prion protein (PrPSc) is diagnostic of prion disease, yet its detection is

frequently difficult. Here, we describe a patient with a PRNP P105T mutation and typical

familial prion disease. Brain PrPSc was undetectable by conventional Western blotting and

barely detectable after phosphotungstate precipitation, where it displayed an atypical pattern

suggestive of noncanonical conformation. Therefore, we used a novel misfolded protein

assay (MPA) that detects PrP aggregates independently of their protease resistance. The

MPA revealed the presence of aggregated PrP in similar amounts as in typical sporadic

Creutzfeldt-Jakob disease. These findings suggest that measurements of PrP aggregation

with the MPA may be potentially more sensitive than protease-based methodologies.


Keywords

familial prion disease, misfolded protein assay, prion.

Corresponding authors:

Adriano Aguzzi, MD PHD, Institute of

Neuropathology, University Hospital of Zurich,

Schmelzbergstrasse 12, Zurich CH-8091,

Switzerland (E-mail: adriano.aguzzi@usz.ch);

Magdalini Polymenidou, PHD, Department of

Cellular and Molecular Medicine, University of

California, San Diego, 9500 Gilman Drive, La

Jolla, CA 92093-0670, USA (E-mail:

mpolymen@ucsd.edu)

Received 2 June 2010; accepted 2 August

2010.

* These authors contributed equally to this

work.

doi:10.1111/j.1750-3639.2010.00439.x

http://www.pathol.uzh.ch/publications/2010/Polymenidou_BrainPath_2010.pdf



Sunday, November 28, 2010

Variably protease-sensitive prionopathy in a PRNP codon 129 heterozygous UK patient with co-existing tau, a synuclein and AB pathology


http://prionopathy.blogspot.com/2010/11/variably-protease-sensitive-prionopathy.html



http://sporadicffi.blogspot.com/



TSS

Thursday, November 19, 2009

Inherited Creutzfeldt–Jakob disease in a Dutch patient with a novel five octapeptide repeat insertion and unusual cerebellar morphology

J Neurol Neurosurg Psychiatry 2009;80:1386-1389 doi:10.1136/jnnp.2008.169359

Short report

Inherited Creutzfeldt–Jakob disease in a Dutch patient with a novel five octapeptide repeat insertion and unusual cerebellar morphology

C Jansen1, J C van Swieten2, S Capellari3, R Strammiello3, P Parchi3, A J M Rozemuller1 + Author Affiliations

1Dutch Surveillance Centre for Prion Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands 2Department of Neurology, Erasmus University Medical Centre, Rotterdam, The Netherlands 3Dipartimento di Scienze Neurologiche, Università di Bologna, Bologna, Italy Correspondence to Dr C Jansen, Dutch Surveillance Centre for Prion Diseases, University Medical Centre Utrecht, Heidelberglaan 100, PO Box 85500, 3508 GA, Utrecht, The Netherlands; c.jansen@umcutrecht.nl Received 2 December 2008 Revised 22 February 2009 Accepted 5 March 2009 Abstract An atypical case of inherited Creutzfeldt–Jakob disease (CJD) is described in a 35-year-old Dutch woman, homozygous for methionine at codon 129 of the prion protein gene (PRNP). The clinical phenotype was characterised by slowly progressive cognitive decline and parkinsonism. Neuropathological findings consisted of scanty spongiosis and only faint to absent immunohistochemical staining for the abnormal prion protein, PrPSc, with patchy deposits in the cerebellar cortex. Purkinje cells were abnormally located in the molecular layer of the cerebellum. Western blot analysis showed the co-occurrence of PrPSc types 1 and 2 with an unusual distribution. Sequence analysis disclosed a novel 120 bp insertion in the octapeptide repeat region of the PRNP, encoding five additional R2 octapeptide repeats. These features define an unusual neuropathological phenotype and novel genotype, further expanding the spectrum of genotype–phenotype correlations in inherited prion diseases and emphasising the need to carry out pre-mortem PRNP sequencing in all young patients with atypical dementias.

snip...

METHODS Case history The patient presented with forgetfulness and difficulties in writing at the age of 35 years, after the birth of her second child. Her family noted that she had become increasingly absentminded and apathetic. Her clinical history was otherwise unremarkable. Her father had suffered from dementia and parkinsonism from the age of 45 years and died at the age of 55 years. At neurological examination, 2.5 years after the first symptoms, the patient was disoriented in time and place, and exhibited echolalia, perseveration and disturbed visual perception. She had a masked face with vertical gaze palsy, and increased tone of the extremities. Neuropsychological evaluation revealed an intact memory with acalculia, agraphia and apraxia. Brain MRI showed generalised cortical atrophy without evidence of hyperintensity or atrophy of either the caudate nucleus or the basal ganglia (fig 1A). The 14-3-3 test in CSF was negative. An electroencephalogram was not recorded. Genetic analysis revealed no abnormalities in the tau protein gene (MAPT), the Presenilin 1 gene (PSEN1) or the Huntingtin gene. Over the next 3 years, rigidity increased with the appearance of a slight tremor in her right hand, without any beneficial effect on levodopa and amantadin treatment. She increasingly developed dysarthria and swallowing problems, and suffered from anxiety and panic attacks. She was admitted to a nursing home where she died from bronchopneumonia at the age of 42 years, 92 months after the clinical onset of the disease.


snip...


DISCUSSION

Seventeen patients with six different 5-OPRI have been described so far in the literature.6 As in other inherited prion diseases, these disorders show a considerable degree of phenotypic variability, partly accounted for by the codon 129 Met/Val polymorphism. Age at onset in codon 129 heterozygous patients is usually later (58.0 years) than in codon 129 homozygous patients (42.3 years).6 Approximately half of these patients show a disease duration of more than 60 months. Although the clinical and pathological features of 5-OPRI mutations are relatively well known, genotype–phenotype correlation has not been clearly established, warranting the description of further genetic cases.

In this report, we describe a novel insertion mutation in PRNP, consisting of five extra R2 octapeptide repeats (R1-(R2)7- R3-R4). The clinical phenotype in our patient was characterised by slowly progressive cognitive decline, parkinsonism, anxiety and a long disease duration of 92 months. Neuropathological findings included scanty spongiosis and faint synaptic or even absent immunohistochemical staining, except for small patchy deposits in the cerebellar cortex, without the characteristic perpendicular orientation to the meningeal outline, as described in other patients with insertion mutations.8 12 An intriguing finding, although described before in three other patients with a 5-OPRI mutation,13 was the abnormal localisation of Purkinje cells in the molecular layer of the cerebellum. The type of abnormalities, combined with the absence of ataxia and significant cerebellar pathology, strongly suggest this defect as being longstanding and likely related to a developmental defect. Thus although largely speculative, the observation may suggest a role for PrPC in cerebellar neuronal migration or in the elimination of misplaced Purkinje cells during development which likely involve the programmed cell death machinery, as recently suggested.14 Furthermore, in the absence of a specific histopathological picture, the observation of misplacement of Purkinje cells in the molecular layer might be a helpful diagnostic clue prompting the suspicion of inherited prion disease with OPRI mutation.

Another interesting finding was the co-occurrence of PrPSc types 1 and 2 in brain homogenates, as demonstrated by immunoblotting. To our knowledge, this has only been described once before in a patient with one extra octapeptide repeat in PRNP, who showed widespread spongiosis and diffuse synaptic immunoreactivity in all cortical lobes.15 In light of the scanty spongiosis and faint immunohistochemical staining in the brain of our patient, the presence of type 2 protein is a peculiar finding, since in methionine homozygotes (MM) at codon 129, type 2 is usually associated with prominent spongiosis with confluent vacuoles and more consistent coarse and perivacuolar deposits of PrPSc in the cerebral cortex.11 Furthermore, type 2 in MM cases preferentially accumulates in the cerebral cortex11 whereas it was mainly detected in the striatum and cerebellum in the present case. The 5-OPRI mutation in this patient was probably inherited in an autosomal dominant pattern but a positive family history in patients with inherited prion disease is not obligate. In all patients with a clinical history of frontotemporal dementia or atypical dementia and abnormal localisation of Purkinje cells in the molecular layer of the cerebellum, inherited prion disease should always be considered and pre-mortem PRNP sequencing should be carried out.

snip...see full text ;





http://jnnp.bmj.com/content/80/12/1386.abstract




http://sporadicffi.blogspot.com/



TSS

Wednesday, August 12, 2009

Neurobiology of Disease A New Transgenic Mouse Model of GSS Syndrome Caused by the A117V Mutation of PRNP

Neurobiology of Disease A New Transgenic Mouse Model of Gerstmann–Sträussler–Scheinker Syndrome Caused by the A117V Mutation of PRNP

Wenbin Yang,1 Julie Cook,1 Benjamin Rassbach,1 Azucena Lemus,2 Stephen J. DeArmond,2 and James A. Mastrianni1

1Department of Neurology, University of Chicago, Chicago, Illinois 60637, and 2Department of Neuropathology, University of California, San Francisco, San Francisco, California 94143

Correspondence should be addressed to James A. Mastrianni, Department of Neurology, University of Chicago, MC2030, 5841 South Maryland Avenue, Chicago, IL 60637. Email: mhtml:%7B33B38F65-8D2E-434D-8F9B-8BDCD77D3066%7Dmid://00000475/!x-usc:mailto:jmastria@uchicago.edu

Gerstmann–Sträussler–Scheinker syndrome (GSS) is a genetic prion disease typified clinically by the development of progressive ataxia and dementia, and histopathologically by the presence of prion protein (PrP) amyloid plaques in the CNS, especially within the cerebellum. Several mutations of the PrP gene (PRNP) are associated with GSS, but only the P102L mutation has been convincingly modeled in transgenic (Tg) mice. To determine whether other mutations carry specific GSS phenotypic information, we constructed Tg mice that express PrP carrying the mouse homolog of the GSS-associated A117V mutation. Tg(A116V) mice express approximately six times the endogenous levels of PrP, develop progressive ataxia by 140 d, and die by 170 d. Compared with a mouse model of transmissible Creutzfeldt–Jakob disease (CJD), the ataxia of Tg(A116V) mice is more prominent, and the course of disease is more protracted, paralleling that observed in human disease. Neuropathology includes mild scattered vacuolation and prominent, mainly cerebellar localized, thioflavin S-positive PrP plaques comprised of full-length PrPA116V. In some mice, more prominent vacuolation or a noncerebellar distribution of PrP plaques was evident, suggesting some variability in phenotype. The biophysical properties of PrP from Tg(A116V) mice and human GSS(A117V) revealed a similarly low fraction of insoluble PrP and a weakly protease-resistant 13 kDa midspan PrP fragment, not observed in CJD. Overall, Tg(A116V) mice recapitulate many clinicopathologic features of GSS(A117V) that are distinct from CJD, supporting PrPA116V to carry specific phenotypic information. The occasional variation in histopathology they exhibit may shed light on a similar observation in human GSS(A117V).

-------------------------------------------------------------------------------- Received June 2, 2009; revised June 30, 2009; accepted July 3, 2009.

Correspondence should be addressed to James A. Mastrianni, Department of Neurology, University of Chicago, MC2030, 5841 South Maryland Avenue, Chicago, IL 60637. Email: mhtml:%7B33B38F65-8D2E-434D-8F9B-8BDCD77D3066%7Dmid://00000475/!x-usc:mailto:jmastria@uchicago.edu




http://www.jneurosci.org/cgi/content/abstract/29/32/10072?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=prion&searchid=1&FIRSTINDEX=0&volume=29&issue=32&resourcetype=HWCIT





http://sporadicffi.blogspot.com/